The Development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates

  1. Gang Ye
  2. Joseph Gallant
  3. Jian Zheng
  4. Christopher Massey
  5. Ke Shi
  6. Wanbo Tai
  7. Abby Odle
  8. Molly Vickers
  9. Jian Shang
  10. Yushun Wan
  11. Lanying Du Dr.
  12. Hideki Aihara
  13. Stanley Perlman
  14. Aaron LeBeau  Is a corresponding author
  15. Fang Li  Is a corresponding author
  1. University of Minnesota, United States
  2. University of Iowa, United States
  3. University of Texas Medical Branch, United States
  4. Lindsley F Kimball Research Institute, United States
  5. Lindsley F Kimball Research Institute, New York Blood Center, United States
1 additional file

Additional files

All additional files

Any figure supplements, source code, source data, videos or supplementary files associated with this article are contained within this zip.

https://cdn.elifesciences.org/articles/64815/elife-64815-supp-v1.zip

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Gang Ye
  2. Joseph Gallant
  3. Jian Zheng
  4. Christopher Massey
  5. Ke Shi
  6. Wanbo Tai
  7. Abby Odle
  8. Molly Vickers
  9. Jian Shang
  10. Yushun Wan
  11. Lanying Du Dr.
  12. Hideki Aihara
  13. Stanley Perlman
  14. Aaron LeBeau
  15. Fang Li
(2021)
The Development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates
eLife 10:e64815.
https://doi.org/10.7554/eLife.64815